Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liarozole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Liarozole | DRUG | - |
Inclusion Criteria: * Subjects of either sex aged 14 years or older. * Clinical diagnosis of lamellar ichthyosis * Women of childbearing potential should use appropriate contraception * Women of childbearing potential should have a negative pregnancy test at screening visit. * Subjects are, except ...
Liarozole is an investigational small molecule being studied for the treatment of lamellar ichthyosis, a rare genetic skin disorder. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Liarozole is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
Liarozole is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 2 trial has been completed, and the drug remains under evaluation for the treatment of lamellar ichthyosis.
Liarozole has been studied in one completed Phase 2 clinical trial, identified as NCT00282724. This trial evaluated the efficacy and safety of two doses of Liarozole compared to placebo in 98 patients with lamellar ichthyosis, across multiple countries including Belgium, Canada, and France.
Liarozole is a distinct investigational compound developed by GSK plc. No alternative names for this drug have been disclosed in public clinical trial records. It is being studied specifically for lamellar ichthyosis.